Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Framycetin + gramicidin + dexamethasone is a topical ophthalmic and otic combination product containing two antibiotics and a corticosteroid, used primarily to treat bacterial infections and associated inflammation of the external eye (e.g. conjunctivitis, blepharitis, keratitis, scleritis) and external ear (e.g. otitis externa). Framycetin is an aminoglycoside antibiotic that binds the 30S ribosomal subunit to inhibit bacterial protein synthesis, providing broad-spectrum activity against many Gram‑positive and Gram‑negative organisms. Gramicidin is a cyclic peptide antibiotic that inserts into bacterial cytoplasmic membranes to form ion channels, disrupting membrane integrity and leading to cell death, with predominant activity against Gram‑positive bacteria. Dexamethasone is a synthetic glucocorticoid that binds intracellular glucocorticoid receptors and modulates gene transcription to exert potent local anti‑inflammatory and immunosuppressive effects, reducing redness, swelling, and discomfort while the antibiotics eradicate susceptible bacteria. The combination is formulated as eye/ear drops for local action with minimal systemic absorption when used appropriately.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on framycetin + gramicidin + dexamethasone.